Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Genetic and antigenic typing of seasonal influenza virus breakthrough cases from a 2008-2009 vaccine efficacy trial
Clinical and Vaccine Immunology, Volume 21, No. 3, Year 2014
Notification
URL copied to clipboard!
Description
Estimations of the effectiveness of vaccines against seasonal influenza virus are guided by comparisons of the antigenicities between influenza virus isolates from clinical breakthrough cases with strains included in a vaccine. This study examined whether the prediction of antigenicity using a sequence analysis of the hemagglutinin (HA) gene-encoded HA1 domain is a simpler alternative to using the conventional hemagglutination inhibition (HI) assay, which requires influenza virus culturing. Specimens were taken from breakthrough cases that occurred in a trivalent influenza virus vaccine efficacy trial involving >43,000 participants during the 2008-2009 season. A total of 498 influenza viruses were successfully subtyped as A(H3N2) (380 viruses), A(H1N1) (29 viruses), B(Yamagata) (23 viruses), and B(Victoria) (66 viruses) from 603 PCR- or culture-confirmed specimens. Unlike the B strains, most A(H3N2) (377 viruses) and all A(H1N1) viruses were classified as homologous to the respective vaccine strains based on their HA1 domain nucleic acid sequence. HI titers relative to the respective vaccine strains and PCR subtyping were determined for 48% (182/380) of A(H3N2) and 86% (25/29) of A(H1N1) viruses. Eighty-four percent of the A(H3N2) and A(H1N1) viruses classified as homologous by sequence were matched to the respective vaccine strains by HI testing. However, these homologous A(H3N2) and A(H1N1) viruses displayed a wide range of relative HI titers. Therefore, although PCR is a sensitive diagnostic method for confirming influenza virus cases, HA1 sequence analysis appeared to be of limited value in accurately predicting antigenicity; hence, it may be inappropriate to classify clinical specimens as homologous or heterologous to the vaccine strain for estimating vaccine efficacy in a prospective clinical trial. Copyright © 2014, American Society for Microbiology. All Rights Reserved.
Authors & Co-Authors
Durviaux, Serge M.
Belgium, Wavre
Glaxosmithkline Pharmaceuticals Sa/nv
Treanor, John Jay
United States, Rochester
University of Rochester Medical Center
Duval, Xavier
France, Paris
Hôpital Bichat-claude-bernard Ap-hp
Esen, Meral
Germany, Tubingen
Institut Für Tropenmedizin
Feldman, Gregory J.
United States, Spartanburg
S. Carolina Pharmaceutical Research
Launay, Odile
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Leroux-Roels, Geert G.
Belgium, Ghent
Universiteit Gent
Nowakowski, Andrzej Marcin
Poland, Warsaw
Wojskowy Instytut Medyczny
Ruíz-Palacios, Guillermo Miguel
Mexico, Tlalpan
Instituto Nacional de la Nutrición Salvador Zubiran
Oostvogels, Lidia C.
Belgium, Wavre
Glaxosmithkline Pharmaceuticals Sa/nv
Walravens, Karl
Belgium, Wavre
Glaxosmithkline Pharmaceuticals Sa/nv
Statistics
Citations: 7
Authors: 11
Affiliations: 12
Identifiers
Doi:
10.1128/CVI.00544-13
ISSN:
15566811
Research Areas
Genetics And Genomics
Study Design
Cohort Study